mRNA Vaccines Market Size, Share, Regional Growth, 2026-2034
- jhon smith
- Apr 29
- 4 min read
Market Overview
According to Fortune Business Insights, the global mRNA vaccines market size was valued at USD 6.01 billion in 2025. The market is projected to grow from USD 6.85 billion in 2026 to USD 25.64 billion by 2034, exhibiting a CAGR of 17.94% during the forecast period. North America dominated the mRNA vaccines market with a market share of 31.47% in 2025.
Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled “mRNA Vaccines Market, 2026-2034.”
The analysis shows that top companies are investing more in mRNA vaccines because of their success during the COVID-19 pandemic and rapid technological advancements. For example, Pfizer Inc. utilized an AI tool, Smart Data Query (SDQ), to speed up the clinical data review process during the pandemic. This trend indicates a strong demand for mRNA vaccines worldwide.
Major Players Profiled in the Market Report:
Moderna Inc. (U.S.)
BioNTech (Germany)
CureVac SE (Germany)
GSK plc (U.K.)
Sanofi (France)
Pfizer Inc. (U.S.)
Gennova Biopharmaceuticals Limited (India)
Walvax Biotechnology Co., Ltd. (China)
Arcturus Therapeutics (U.S.)
Segments
Rise in Demand During Pandemic to Propel COVID-19 Vaccines Segment GrowthBased on type, the market is segmented into COVID-19 vaccines and non-COVID-19 vaccines. The COVID-19 vaccines segment holds the largest market share and dominates the market owing to the surge in demand and emergency use authorizations granted during the global pandemic.
Emergence of New Variants to Drive COVID-19 Infection Segment ExpansionBy indication, the market is categorized into COVID-19 infection, Respiratory Syncytial Virus (RSV) infection, and others. The COVID-19 infection segment is leading the market due to the presence of approved mRNA vaccines and the ongoing need for booster doses and advanced vaccines to combat new variants.
High Convenience and Government Support to Dominate Hospital & Retail Pharmacies SegmentBased on distribution channel, the market is segmented into hospital & retail pharmacies, government suppliers, and others. The hospital & retail pharmacies segment holds the largest market share owing to their high preference among consumers as these were the main centers for vaccine administration during the pandemic, supported by government programs.
Report Coverage
The report offers:
Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
Comprehensive insights into regional developments.
List of major industry players.
Key strategies adopted by the market players.
The latest industry developments include product launches, partnerships, mergers, and acquisitions.
Drivers & Restraints
Increase in R&D Activities to Propel Market GrowthThe rapid growth in R&D activities has raised the demand for mRNA-based vaccines. The successful deployment of COVID-19 vaccines has spurred research for other diseases like influenza and RSV, and both public and private sectors are ramping up investments. For instance, in September 2023, Moderna Inc. announced plans to invest approximately USD 25 billion in R&D from 2024 to 2028, boosting the mRNA vaccines market growth.
However, the strict rules and regulations for product approvals may hamper market growth. Delays in obtaining licenses and challenges in standardizing production processes and ensuring quality control can lead to regulatory bottlenecks.
Regional Insights
Presence of Key Players and R&D Investment Propels Market Growth in North AmericaNorth America holds the dominant mRNA vaccines market share and is projected to experience growth during the forecast period. The region’s growth is attributed to the presence of key market players, a strong emphasis on R&D, and significant government investment. For instance, the U.S. government invested approximately USD 31.9 billion in the development and procurement of mRNA COVID-19 vaccines.
Asia Pacific is one of the fastest-growing regions in the market. The growth is attributed to the rise in the prevalence of infectious diseases, an increasing number of clinical trials, and growing government support for research and development in nations including China, Japan, and India.
mRNA Vaccines Market Future Growth
The mRNA vaccines market is experiencing robust growth, fueled by technological advancements and expanding applications. The use of artificial intelligence in clinical trials and continuous improvements in delivery technologies, such as Lipid Nanoparticles (LNPs) and self-amplifying mRNA, are enhancing efficacy and reducing costs. Today's research is increasingly focused on expanding the use of mRNA vaccines beyond COVID-19 to treat a range of infectious and autoimmune diseases. The speed, flexibility, and potential cost gains of mRNA technology are key drivers for future growth in developing individualized therapies.
Competitive Landscape
Introduction of New Products and Strong Pipelines to Propel Market GrowthThe market is concentrated, featuring prominent players like Pfizer Inc., Moderna Inc., and BioNTech. These leading companies are accelerating growth through strategic initiatives such as developing new products and maintaining strong pipelines. For example, Moderna is expanding its pipeline to include vaccines for RSV, HIV, and other rare diseases. Pfizer, in collaboration with BioNTech, developed the world's first approved mRNA COVID-19 vaccine. Their proactive approach to innovation and strategic collaborations continues to fuel the market’s momentum.
Key Industry Development
September 2023: Moderna, Inc. expanded its scope for mRNA medicines by showing positive clinical results for rare diseases, cancer, and infectious diseases.
August 2023: CureVac N.V., in collaboration with GSK, developed the dosing of the first participant in the phase 2 study of monovalent and bivalent modified mRNA COVID-19 vaccine.
Comments